Microbio Co., Ltd. (TPEX:4128)

Market Cap	8.47B -37.1%
Revenue (ttm)	1.94B +9.8%
Net Income	-691.94M
EPS	-1.18
Shares Out	588.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,145,326
Open	14.40
Previous Close	14.35
Day's Range	14.35 - 14.60
52-Week Range	14.20 - 30.30
Beta	0.48
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Microbio

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Mic...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2000
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4128

Financial Performance

In 2025, Microbio's revenue was 1.89 billion, an increase of 9.94% compared to the previous year's 1.72 billion. Losses were -757.75 million, -31.16% less than in 2024.